Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Apr 15, 2021; 13(4): 295-304
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.295
Published online Apr 15, 2021. doi: 10.4251/wjgo.v13.i4.295
Table 3 Grade 3 or worse adverse events
Adverse event | Second-line, n = 22 | Salvage therapy, n = 19 | ||
Leukopenia | 0 | (0) | 2 | (11) |
Neutropenia | 3 | (14) | 2 | (11) |
Febrile neutropenia | 1 | (5) | 0 | (0) |
Vomiting | 1 | (5) | 0 | (0) |
Diarrhea | 0 | (0) | 1 | (5) |
Peripheral sensory neuropathy | 0 | (0) | 2 | (11) |
Hypertension | 2 | (9) | 1 | (5) |
Proteinuria | 1 | (5) | 2 | (11) |
Perianal abscess | 1 | (5) | 1 | (5) |
- Citation: Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021; 13(4): 295-304
- URL: https://www.wjgnet.com/1948-5204/full/v13/i4/295.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i4.295